Ruoxi Chen serves as Independent Director of the Company. Mr. Chen has been employed at Warburg Pincus, where he is currently a Principal, focusing on healthcare and consumer investments. Mr. Chen previously worked as an Associate at The Carlyle Group from 2007 to 2009 and in investment banking at Citigroup Global Markets from 2005 to 2007. Mr. Chen received a B.S. in economics and computer science from Duke University and an M.B.A. from Harvard Business School.
As the Independent Director of Silk Road Medical Inc, the total compensation of Ruoxi Chen at Silk Road Medical Inc is $134,403. There are 8 executives at Silk Road Medical Inc getting paid more, with Erica Rogers having the highest compensation of $3,679,060.
Ruoxi Chen is 35, he's been the Independent Director of Silk Road Medical Inc since 2016. There are 13 older and no younger executives at Silk Road Medical Inc. The oldest executive at Silk Road Medical Inc is Jack Lasersohn, 66, who is the Independent Director.
Ruoxi's mailing address filed with the SEC is C/O WARBURG PINCUS & CO., 450 LEXINGTON AVENUE, NEW YORK, NY, 10017.
Over the last 6 years, insiders at Silk Road Medical Inc have traded over $925,682,871 worth of Silk Road Medical Inc stock and bought 14,200 units worth $302,033 . The most active insiders traders include X Finance, L.P.Wpx Gp, L.P...., Pincus & Co.Kaye Charles R ... és Pincus & Co.Warburg Pincus .... On average, Silk Road Medical Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,280,712. The most recent stock trade was executed by Kevin M Klemz on 19 August 2024, trading 2,268 units of SILK stock currently worth $61,463.
silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th
Silk Road Medical Inc executives and other stock owners filed with the SEC include: